Renaissance Capital logo

Axcella Health Priced, Nasdaq: AXLA

Developing amino acid-based therapies to treat liver and other diseases.

Industry: Health Care

First Day Return: -31.0%

Industry: Health Care

We are a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Our AXA Candidates are generated from our proprietary, human-focused AXA Development Platform and harness the power of EMMs, a broad family of molecules that fundamentally impact and regulate human metabolism. Using our AXA Development Platform, we have rapidly generated a pipeline of AXA Candidates that are novel compositions of EMMs engineered in distinct ratios and designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Our AXA Candidates are administered orally and anchored by amino acids, which have a history of safe use as food. As such, we expect our AXA Candidates may also be combinable with other modalities. We believe our current dataset supports the potential of our AXA Candidates to support and modulate the metabolic pathways they target with favorable safety profiles. These features may make them an attractive development opportunity with significant commercial potential.
more less
IPO Data
IPO File Date 04/12/2019
Offer Price $20.00
Price Range $20.00 - $22.00
Offer Shares (mm) 3.6
Deal Size ($mm) $71
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/08/2019
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $71
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 2008
Employees at IPO 49
Website www.axcellahealth.com

Axcella Health (AXLA) Performance